PAYLESS COMPOUNDERS, LLC

FDA Class II Recall: PAYLESS COMPOUNDERS' Semaglutide Injectable Faces Sterility Assurance Deficiencies

PAYLESS COMPOUNDERS, LLC has initiated a Class II recall for 91 vials of its Semaglutide-Glycine-Cyanocobalamin Injectable due to a lack of sterility assurance. This event underscores critical supply chain and regulatory risks for procurement, regulatory affairs, and business development executives sourcing compounded sterile products, demanding immediate review of supplier qualification protocols.